drugset
Drugs / SHY-ONC6
last change Aug 2026 re-read 3 minutes ago

SHY-ONC6

Developed for
colon carcinoma · gastric cancer · hepatocellular carcinoma · hormone receptor-positive breast cancer · hormone-resistant prostate carcinoma · mesothelioma · non-small cell lung carcinoma · soft tissue sarcoma
+1 more · triple-negative breast carcinoma
Investigated by
SHY Therapeutics

Trials 1

today NCT07705334 · Ph 1
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07705334 Jun 2026 → May 2027 expected colon carcinoma, gastric cancer, hepatocellular carcinoma, hormone receptor-positive breast cancer +5 SHY Therapeutics Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2026-08-04 SHY Therapeutics SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid Tumors shytherapeutics.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SHY-ONC6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07705334 ↗
Action Inhibit “SHY-ONC6, a Novel Proteasome Inhibitor” NCT07705334 ↗
Route Oral “administered orally” NCT07705334 ↗